Geneva, June 8 -- International Clinical Trials Registry received information related to the study (TCTR20260530001) titled 'Sequential Therapy with Docetaxel and Abiraterone Acetate in Castration-Resistant Prostate Cancer: Real-World Survival Analysis' on May 30.
Study Type: Observational
Primary Sponsor: N/A
Condition:
A retrospective study comparing the effective sequencing strategy between abiraterone and docetaxel in metastatic castration - resistant prostate cancer in Ramathibodi Hospital, Thailand.
Prostatic Neoplasms, Castration-Resistant, Drug Sequencing, Real-World Evidence
Prostatic Neoplasms, Castration-Resistant, Drug Sequencing, Real-World Evidence
Intervention:
Abiraterone acetate was administered as first-line treat...